Impact of four-week rifaximin treatment on abdominal symptoms, psychological state and gut microbiome in diarrhea-predominant irritable bowel syndrome: a pilot study.

Previous studies have revealed the effect of two-week rifaximin treatment on abdominal symptoms and gut microbiota in diarrhea-predominant irritable bowel syndrome (IBS-D), but they failed to observe the influence of rifaximin intervention for a long…

Preview only. Read the full abstract at the source